NASDAQ:FBIO - Fortress Biotech Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fortress Biotech Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.96 +0.17 (+6.09 %) (As of 02/16/2020 04:00 PM ET) Add Today's Range$2.84Now: $2.96▼$3.1150-Day Range$2.23MA: $2.54▼$2.9652-Week Range$1.20Now: $2.96▼$3.11Volume995,293 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Fortress Biotech, Inc develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A Current SymbolNASDAQ:FBIO Previous Symbol CUSIP21976U10 CIK1429260 WebN/A PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees68 Outstanding SharesN/AMarket CapN/A Next Earnings Date3/16/2020 (Estimated) OptionableOptionable Receive FBIO News and Ratings via Email Sign-up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:FBIO Rates by TradingView Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions What is Fortress Biotech's stock symbol? Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO." How were Fortress Biotech's earnings last quarter? Fortress Biotech (NASDAQ:FBIO) announced its earnings results on Friday, August, 9th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.46) by $0.22. The biopharmaceutical company earned $9.25 million during the quarter, compared to the consensus estimate of $7.51 million. View Fortress Biotech's Earnings History. When is Fortress Biotech's next earnings date? Fortress Biotech is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Fortress Biotech. What price target have analysts set for FBIO? 5 analysts have issued 12 month price targets for Fortress Biotech's stock. Their forecasts range from $4.00 to $19.00. On average, they expect Fortress Biotech's stock price to reach $9.80 in the next year. This suggests a possible upside of 231.1% from the stock's current price. View Analyst Price Targets for Fortress Biotech. What is the consensus analysts' recommendation for Fortress Biotech? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fortress Biotech. What are Wall Street analysts saying about Fortress Biotech stock? Here are some recent quotes from research analysts about Fortress Biotech stock: 1. According to Zacks Investment Research, "Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. " (7/15/2019) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $11 price target. Our valuation is based on our clinical net present value (NPV) model, which derives value from across Fortress’ subsidiaries. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (5/13/2019) Has Fortress Biotech been receiving favorable news coverage? News articles about FBIO stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fortress Biotech earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Fortress Biotech. Are investors shorting Fortress Biotech? Fortress Biotech saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,090,000 shares, an increase of 64.2% from the December 31st total of 664,000 shares. Based on an average daily trading volume, of 328,600 shares, the days-to-cover ratio is presently 3.3 days. Approximately 2.2% of the shares of the stock are short sold. View Fortress Biotech's Current Options Chain. Who are some of Fortress Biotech's key competitors? Some companies that are related to Fortress Biotech include Amgen (AMGN), Celgene (CELG), Alexion Pharmaceuticals (ALXN), Alnylam Pharmaceuticals (ALNY), Arena Pharmaceuticals (ARNA), ArQule (ARQL), Achillion Pharmaceuticals (ACHN), Osiris Therapeutics (OSIR), SIGA Technologies (SIGA), AMAG Pharmaceuticals (AMAG), BioTime (BTX), AVEO Pharmaceuticals (AVEO), Vical (VICL), ImmunoCellular Therapeutics (IMUC) and Achieve Life Sciences (ACHV). What other stocks do shareholders of Fortress Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Geron (GERN), Agile Therapeutics (AGRX), Advanced Micro Devices (AMD), Vaxart (VXRT), Protalix Biotherapeutics (PLX), Aduro BioTech (ADRO) and Anavex Life Sciences (AVXL). Who are Fortress Biotech's key executives? Fortress Biotech's management team includes the folowing people: Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 64)Dr. Eric K. Rowinsky, Co-Vice Chairman & Consultant (Age 62)Mr. Michael S. Weiss, Exec. Vice Chairman of Strategic Devel. (Age 53)Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 57)Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 65) Who are Fortress Biotech's major shareholders? Fortress Biotech's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Cpwm LLC (0.57%), Renaissance Technologies LLC (0.52%), Shikiar Asset Management Inc. (0.44%), Oxford Asset Management LLP (0.35%), Credit Suisse AG (0.16%) and Bank of New York Mellon Corp (0.12%). Company insiders that own Fortress Biotech stock include George Avgerinos and Robyn Hunter. View Institutional Ownership Trends for Fortress Biotech. Which institutional investors are selling Fortress Biotech stock? FBIO stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP and State Street Corp. View Insider Buying and Selling for Fortress Biotech. Which institutional investors are buying Fortress Biotech stock? FBIO stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Oxford Asset Management LLP, Shikiar Asset Management Inc., Credit Suisse AG, Bank of New York Mellon Corp, Goldman Sachs Group Inc., Banco Bilbao Vizcaya Argentaria S.A. and Alpine Global Management LLC. View Insider Buying and Selling for Fortress Biotech. How do I buy shares of Fortress Biotech? Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Fortress Biotech's stock price today? One share of FBIO stock can currently be purchased for approximately $2.96. MarketBeat Community Rating for Fortress Biotech (NASDAQ FBIO)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 275 (Vote Outperform)Underperform Votes: 249 (Vote Underperform)Total Votes: 524MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe FBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2020 by MarketBeat.com StaffFeatured Article: Debt-To-Equity Ratio
